Ultime notizie per MoonLake (NASDAQ:MLTX) Azioni

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

News

Price Target

Reiteration

Analyst Ratings

MLTX

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

The additional capital strengthens MoonLake's balance sheet and provides financial support to rapidly advance sonelokimab and bring to market an investigational ~40 kDa humanized Nanobody designed to directly target sites of inflammation by inhibiting all relevant IL-17 dimers (namely the IL-17A/A, IL-17A/F, and IL-17F/F dimers) and penetrating difficult-to-reach inflamed tissues.

HTGC

MoonLake Enters Agreement With Hercules Capital For Up To $500M In Non-Dilutive Capital

WIIM

MoonLake Immunotherapeutics shares are trading higher after RBC Capital initiated coverage on the stock with an Outperform rating and announced a price target of $67.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Evercore ISI Group analyst Daniel Markowitz initiated coverage on West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) with an Outperform rating and announced a price target of $275. West Pharmaceutical shares closed at $231.46 on Monday. <a href="https://www.benzinga.com/quote/WST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Alpha Cognition Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) with a Buy rating and announced a price target of $20. Alpha Cognition shares closed at $5.51 on Monday. <a href="https://www.benzinga.com/quote/ACOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Maheep Mandloi initiated coverage on Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) with a Neutral rating and announced a price target of $28. Bloom Energy shares closed at $24.19 on Monday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Joe Flynn initiated coverage on Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy rating and announced a price target of $2.5. Canaan shares closed at $1.07 on Monday. <a href="https://www.benzinga.com/quote/CAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Brian Abrahams initiated coverage on MoonLake Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with an Outperform rating and announced a price target of $67. MoonLake shares closed at $38.67 on Monday. <a href="https://www.benzinga.com/quote/MLTX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WST stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png" alt="" class="wp-image-829880" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/18113555/image-150.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44355158/jim-cramer-says-this-tech-stock-is-a-meme-stock-recommends-buying-accenture">Jim Cramer Calls This Stock A &#8216;Meme Stock,&#8217; Recommends Buying Accenture</a></li>
</ul>
Photo: Shutterstock

Initiation

Markets

Trading Ideas

ACOG

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

RBC Capital analyst Brian Abrahams initiates coverage on MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and announces Price Target of $67.

RBC Capital Initiates Coverage On MoonLake with Outperform Rating, Announces Price Target of $67

Goldman Sachs analyst Richard Law maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and lowers the price target from $82 to $73.

Goldman Sachs Maintains Buy on MoonLake, Lowers Price Target to $73

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Needham analyst Serge Belanger maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and raises the price target from $62 to $66.

Needham Maintains Buy on MoonLake, Raises Price Target to $66

MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.60) by 20 percent. This is a 620 percent decrease over losses of $(0.10) per share from the same period last year.

Earnings

MoonLake Q4 2024 GAAP EPS $(0.72) Misses $(0.60) Estimate, Year-end Cash, Cash Equivalents And Short-term Marketable Debt Securities Of $448M Expected To Providing Cash Runway To At Least The End Of 2026

MoonLake Immunotherapeutics shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $62 to $82.

Goldman Sachs analyst Richard Law upgrades MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) from Neutral to Buy and raises the price target from $62 to $82.

Upgrades

Goldman Sachs Upgrades MoonLake to Buy, Raises Price Target to $82

The clinical program for sonelokimab now includes patients with adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis, in addition to adult patients with HS and active psoriatic arthritis.&nbsp;
This increases the number of clinical trials led by MoonLake to ten and aligns with the plan to enroll over 3,000 patients in clinical trials with sonelokimab since the Company was founded in 2021.

Biotech

Health Care

General

MoonLake Immunotherapeutics Announced That Patients Have Been Screened In Three New Trials Across Three New Indications To Evaluate Sonelokimab To Treat Inflammatory Disease

MoonLake Immunotherapeutics Screens First Patients In Phase 3 IZAR Program

Wedbush analyst Yun Zhong assumes MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating and lowers Price Target of $73.

Wedbush Assumes MoonLake at Outperform, Lowers Price Target of $73

Cantor Fitzgerald analyst Prakhar Agrawal reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on MoonLake

Press Releases

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Clear Street Launches Healthcare & Biotechnology Equity Research

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Financing

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Comments

MoonLake

Notizie

Ultime notizie per MoonLake (NASDAQ:MLTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO